During the past decade, CHU de Bordeaux conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 10 clinical trials were completed, i.e. on average, 21.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 6 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Bordeaux" #1 sponsor was "University Hospital, Bordeaux" with 22 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored, "Nantes University Hospital" with 3 trials sponsored and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Bordeaux" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 1 trials as a collaborator, "Caris Life Sciences" with 1 trials as a collaborator and "Centre National de la Recherche Scientifique, France" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Bordeaux" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Pulmonary Arterial Hypertension" (3 trials), "Alzheimer Disease" (2 trials), "Atrial Fibrillation" (2 trials) and "Chronic Obstructive Pulmonary Disease" (2 trials). Many other conditions were trialed in "CHU de Bordeaux" in a lesser frequency.

Most popular intervention types in "CHU de Bordeaux" are "Drug" (34 trials), "Device" (11 trials), "Other" (9 trials), "Biological" (6 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Alectinib" (3 trials), "MRI" (3 trials), "Avelumab" (2 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Bordeaux" are 63 trials for "All" genders.

Currently, there are NaN active trials in "CHU de Bordeaux". 2 are not yet recruiting, 14 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in CHU de Bordeaux, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Bordeaux, 5 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 12 trials that are defined as “Not Applicable".